Ultrafiltration for the treatment of diuretic-resistant, recurrent, acute decompensated heart failure: experience in a single center
- PMID: 20442667
- DOI: 10.2459/JCM.0b013e3283383275
Ultrafiltration for the treatment of diuretic-resistant, recurrent, acute decompensated heart failure: experience in a single center
Abstract
Purpose of study: We report our experience with ultrafiltration to remove fluid overload in patients with diuretic-resistant, decompensated, congestive heart failure.
Methods: From 2005 to 2008, 42 patients with heart failure and left ventricular ejection fraction less than 40% were treated with ultrafiltration. Patients were hospitalized for acute decompensation. Mean age was 69 years (67% men). Cause of heart failure was ischemic in 52% of cases. New York Heart Association (NYHA) class was III (64%) or IV (36%). All patients were on optimal heart failure drugs. Average dose of furosemide before ultrafiltration was 250 mg. Exclusion criteria were contraindications to anticoagulants, hematocrit more than 50%, glomerular filtration rate less than 30 ml/min and cardiogenic shock. Ultrafiltration was performed using a venous femoral bilumen catheter and anticoagulation with heparin.
Results: Each patient underwent one to four ultrafiltration treatments (total 70). Mean duration of a treatment was 6 h. Eighty-six percent of treatments removed more than 4000 ml of fluids; 10% removed 2000-4000 ml; 4% removed less than 2000 ml (1600-6900 ml). One ultrafiltration was aborted because of persistent hypotension. Other complications include two cases of bleeding from vascular access and six cases of worsened renal function. One patients required dialysis. Six-month mortality after ultrafiltration was 26%. Hospitalization rate, 6 months after, was 30% (compared to 66% 6 months before). Average furosemide dose, 6 months after, was 125 mg.
Conclusion: Ultrafiltration removed fluid overload in diuretic-resistant, severe, congestive heart failure in our single-center experience. Six months after ultrafiltration, hospitalization rates were reduced by 36% and furosemide dose was 50% lower, compared to the previous 6 months. Worsened renal function was the most common complication (14% of patients).
Similar articles
-
Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center.J Card Fail. 2006 Dec;12(9):707-14. doi: 10.1016/j.cardfail.2006.08.210. J Card Fail. 2006. PMID: 17174232
-
Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol. 2005 Dec 6;46(11):2047-51. doi: 10.1016/j.jacc.2005.05.099. Epub 2005 Nov 9. J Am Coll Cardiol. 2005. PMID: 16325040
-
A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.J Card Fail. 2008 Feb;14(1):1-5. doi: 10.1016/j.cardfail.2007.09.007. J Card Fail. 2008. PMID: 18226766 Clinical Trial.
-
Decongestive treatment of acute decompensated heart failure: cardiorenal implications of ultrafiltration and diuretics.Am J Kidney Dis. 2011 Dec;58(6):1005-17. doi: 10.1053/j.ajkd.2011.07.023. Epub 2011 Oct 19. Am J Kidney Dis. 2011. PMID: 22014726 Review.
-
Unloading therapy by intravenous diuretic in chronic heart failure: a double-edged weapon?J Cardiovasc Med (Hagerstown). 2010 Aug;11(8):571-4. doi: 10.2459/JCM.0b013e32833d37b9. J Cardiovasc Med (Hagerstown). 2010. PMID: 20588135 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials